3%~14% Glycosylated Hemoglobin Detection Reagen (HbA1c) Performance
Index
Overview of HbA1c
Glycated hemoglobin (HbA1c) is the product of the combination of
hemoglobin in the red blood cells of the human blood and the sugars
in the serum. The combination of blood sugar and hemoglobin to
produce glycated hemoglobin is an irreversible reaction. The
occurrence of this reaction is directly proportional to the blood
sugar concentration and can be maintained for about 120 days.
Therefore, the glycosylated hemoglobin test can reflect the
patient's blood glucose control in the past 8 to 12 weeks.
HbA1c Performance Index
| Detection range | sample size | Sample type | Test time |
| 3％~14％ | 10μl | Whole Blood | 15min |
Clinical significance of HbA1c
- Early screening and diagnosis of diabetes
- Effect evaluation of blood sugar control program
- Prediction of chronic complications of diabetes
- Distinguishing Stress Hyperglycemia and Diabetes
- Diagnosis and treatment monitoring of gestational diabetes (GDM),
etc.
| Glycated hemoglobin control objectives | Adapt to the crowd |
| <6% | ①Newly diagnosed, young, without complications and concomitant
diseases, and no adverse effects such as hypoglycemia and weight
gain in hypoglycemic treatment; ②Those who do not need hypoglycemic
intervention; ③Diabetes complicated with pregnancy; ④Diabetes
discovered during pregnancy |
| <6.5% | ①<65 years old, no diabetic complications and serious
concomitant diseases; ②Planned gestational diabetes patients |
| <7% | ①Patients younger than 65 years old who use insulin therapy;
②Patients ≥65 years old, no risk of hypoglycemia, good organ
function, and survival time >15 years; ③Patients with planned
gestational diabetes who receive insulin therapy |
| ≤7.5% | People with existing or very high risk of cardiovascular disease |
| <8% | ≥65 years old, expected survival period is 5-15 years |
| <9% | ①≥65 years of age or suffering from malignant tumors, expected
survival time <5 years; ②Patients at high risk of hypoglycemia;
③Difficulties in implementing the treatment plan, such as mental or
intellectual or visual impairment, poor medical conditions, etc. |
Application Department
Cardiology, laboratory, emergency, ICU, oncology,
Nephrology,Pediatrics, endocrinology, gynecology, geriatrics,
respiratory, thoracic surgery,Gastroenterology, Urology, etc
Clinical comparison of HbA1c
Company profile
Zhongxiu Science And Technology Co.,Ltd., is a high-tech enterprise
engaged in the research and development, production and operation
of in vitro diagnostic products. The in vitro diagnostic products
developed by the company cover POCT series, microbial series,
biochemical series and immune series reagents and supporting
instruments.
The company has always adhered to the core concept of "fast and
accurate, living up to life", committed to providing society with
excellent products and services, and contributing to the cause of
human health.
